awmsg logo



olanzapine (ZypAdhera®)


Reference No. 2991

Publication date:
27/07/2016


Appraisal information

olanzapine (ZypAdhera®) 210 mg powder and solvent for prolonged-release suspension for injection
olanzapine (ZypAdhera®) 300 mg powder and solvent for prolonged-release suspension for injection
olanzapine (ZypAdhera®) 405 mg powder and solvent for prolonged-release suspension for injection


Company: Eli Lilly & Co Ltd
BNF category: Unspecified
NMG meeting date: 11/05/2016
AWMSG meeting date: 15/06/2016
   
   
Submission Type: Resubmission
Status: Recommended with restrictions
Advice No: 1516
Ministerial ratification: 26/07/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Olanzapine (ZypAdhera®) is recommended as an option for restricted use within NHS Wales. Olanzapine (ZypAdhera®) is licensed for the maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine. Olanzapine (ZypAdhera®) is restricted for use in a subpopulation of patients more appropriately managed with a long acting injection formulation because of difficulties adhering to an oral olanzapine regimen, indicated by recurrent relapse or exacerbation of symptoms. Olanzapine (ZypAdhera®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download